{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:08:25Z","timestamp":1789564105545,"version":"build-2803163510"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.7075","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T04:57:41Z","timestamp":1620277061000},"page":"e217075","source":"Crossref","is-referenced-by-count":58,"title":["Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs"],"prefix":"10.1001","volume":"4","author":[{"given":"Jennifer E.","family":"Miller","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale Program for Biomedical Ethics and Bioethics International, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Mello","sequence":"additional","affiliation":[{"name":"Stanford Law School, Freeman Spogli Institute for International Studies, Stanford University, Stanford, California"},{"name":"Department of Health Research and Health Policy, Department of Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Wallach","sequence":"additional","affiliation":[{"name":"Department of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Gudbranson","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Bohlig","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary P.","family":"Gross","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Bach","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"issue":"10","key":"zoi210232r1","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1073\/pnas.1715368115","article-title":"Contribution of NIH funding to new drug approvals 2010-2016.","volume":"115","author":"Galkina Cleary","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"zoi210232r2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.mayocp.2015.01.014","article-title":"Why are cancer drugs so expensive in the United States, and what are the solutions?","volume":"90","author":"Kantarjian","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"zoi210232r5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1377\/hlthaff.2012.0920","article-title":"Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.","volume":"32","author":"Kanavos","year":"2013","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"zoi210232r6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJMsb0803929","article-title":"Ethical and scientific implications of the globalization of clinical research.","volume":"360","author":"Glickman","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi210232r7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1740774519839391","article-title":"Globalization of clinical trials: variation in estimated regional costs of pivotal trials, 2015-2016.","volume":"16","author":"Qiao","year":"2019","journal-title":"Clin Trials"},{"issue":"6","key":"zoi210232r8","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/ejhf.2018.20.issue-6","article-title":"Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years.","volume":"20","author":"Vaduganathan","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"zoi210232r9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017917","article-title":"Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.","volume":"7","author":"Miller","year":"2017","journal-title":"BMJ Open"},{"key":"zoi210232r10","doi-asserted-by":"publisher","first-page":"l4217","DOI":"10.1136\/bmj.l4217","article-title":"Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.","volume":"366","author":"Miller","year":"2019","journal-title":"BMJ"},{"issue":"11","key":"zoi210232r11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009758","article-title":"Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.","volume":"5","author":"Miller","year":"2015","journal-title":"BMJ Open"},{"key":"zoi210232r13","doi-asserted-by":"publisher","first-page":"k2031","DOI":"10.1136\/bmj.k2031","article-title":"Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.","volume":"361","author":"Wallach","year":"2018","journal-title":"BMJ"},{"issue":"4","key":"zoi210232r18","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1111\/epi.1997.38.issue-s4","article-title":"Don\u2019t test, do sell: legal implications of inclusion and exclusion of women in clinical drug trials.","volume":"38","author":"Herz","year":"1997","journal-title":"Epilepsia"},{"key":"zoi210232r19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-pharmtox-010814-124614","article-title":"How good is \u201cevidence\u201d from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?","volume":"55","author":"Naci","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"15","key":"zoi210232r20","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1001\/archinte.162.15.1682","article-title":"Representation of the elderly, women, and minorities in heart failure clinical trials.","volume":"162","author":"Heiat","year":"2002","journal-title":"Arch Intern Med"},{"issue":"3","key":"zoi210232r22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033559","article-title":"Underrepresentation of elderly people in randomised controlled trials: the example of trials of 4 widely prescribed drugs.","volume":"7","author":"Konrat","year":"2012","journal-title":"PLoS One"},{"issue":"27","key":"zoi210232r23","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials.","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi210232r24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","article-title":"Participation of patients 65 years of age or older in cancer clinical trials.","volume":"21","author":"Lewis","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi210232r25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ejim.2005.08.001","article-title":"Under-representation of the elderly in clinical trials.","volume":"16","author":"Rehman","year":"2005","journal-title":"Eur J Intern Med"},{"issue":"22","key":"zoi210232r26","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.","volume":"22","author":"Talarico","year":"2004","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi210232r27","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities.","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"4","key":"zoi210232r28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/medethics-2011-100118","article-title":"Sharing the benefits of research fairly: two approaches.","volume":"38","author":"Millum","year":"2012","journal-title":"J Med Ethics"},{"issue":"6","key":"zoi210232r30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/15265161.2010.483183","article-title":"For-profit clinical trials in developing countries: those troublesome patient benefits.","volume":"10","author":"Schuklenk","year":"2010","journal-title":"Am J Bioeth"},{"key":"zoi210232r31","first-page":"289","article-title":"Global and regional drug regulatory harmonization initiatives.","volume":"44","author":"Lakkis","year":"2010","journal-title":"Ther Innov Regul Sci"},{"issue":"338","key":"zoi210232r32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1396","article-title":"The need for global regulatory harmonization: a public health imperative.","volume":"8","author":"Zerhouni","year":"2016","journal-title":"Sci Transl Med"},{"issue":"14","key":"zoi210232r33","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1056\/NEJMc1700103","article-title":"Regulatory review of new therapeutic agents: FDA versus EMA, 2011-2015.","volume":"376","author":"Downing","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi210232r34","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s10637-011-9638-0","article-title":"The notorious \u201cdrug lag\u201d for oncology drugs in Japan.","volume":"29","author":"Yonemori","year":"2011","journal-title":"Invest New Drugs"},{"issue":"3","key":"zoi210232r35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ejpb.2007.07.013","article-title":"Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.","volume":"68","author":"Tsuji","year":"2008","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"zoi210232r36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/cpt.2019.105.issue-1","article-title":"A significant anticancer drug approval lag between Japan and the United States still exists for minor cancers.","volume":"105","author":"Yamashita","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"zoi210232r37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/0020731419898335","article-title":"Do free trade agreements matter to drug lag? recent evidence from Korea after the Korea\u2013U.S. Free Trade Agreement.","volume":"50","author":"Son","year":"2020","journal-title":"Int J Health Serv"},{"issue":"9","key":"zoi210232r38","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1377\/hlthaff.2013.1307","article-title":"The hidden cost of low prices: limited access to new drugs in India.","volume":"33","author":"Berndt","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"11","key":"zoi210232r39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166515","article-title":"Speeding access to vaccines and medicines in low- and middle-income countries: a case for change and a framework for optimized product market authorization.","volume":"11","author":"Ahonkhai","year":"2016","journal-title":"PLoS One"},{"key":"zoi210232r40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13023-016-0392-4","article-title":"The availability and affordability of orphan drugs for rare diseases in China.","volume":"11","author":"Gong","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"zoi210232r41","doi-asserted-by":"crossref","DOI":"10.1177\/2399202618810121","article-title":"Improving market access to rare disease therapies: a worldwide perspective with recommendations to the industry.","author":"Lucas","year":"2018","journal-title":"Med Access Point Care"},{"issue":"1","key":"zoi210232r42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40545-020-00234-2","article-title":"Registration and local production of essential medicines in Uganda.","volume":"13","author":"Brhlikova","year":"2020","journal-title":"J Pharm Policy Pract"},{"key":"zoi210232r29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/oso\/9780195168655.003.0068","volume-title":"The Oxford Textbook of Clinical Research Ethics","author":"London","year":"2008"},{"key":"zoi210232r3","unstructured":"Langreth? R, Migliozzi? B, Gokhale? K. The U.S. pays a lot more for top drugs than other countries. Bloomberg. Published December 18, 2015. Accessed November 20, 2020. https:\/\/www.bloomberg.com\/graphics\/2015-drug-prices"},{"key":"zoi210232r4","unstructured":"Pitts? P. How other countries freeload on U.S. drug research. Wall Street Journal. Published February 21, 2017. Accessed November 20, 2020. https:\/\/www.wsj.com\/articles\/how-other-countries-freeload-on-u-s-drug-research-1487722580"},{"key":"zoi210232r12","unstructured":"US Food and Drug Administration. Priority review. Published January 4, 2018. Accessed September 3, 2020. https:\/\/www.fda.gov\/ForPatients\/Approvals\/Fast\/ucm405405.htm"},{"key":"zoi210232r14","unstructured":"World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. ATC\/DDD index 2017. Accessed March 15, 2020. https:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"zoi210232r15","unstructured":"The World Bank. World Bank country and lending groups. Accessed March 2020. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"key":"zoi210232r16","unstructured":"Council for International Organizations of Medical Sciences; World Health Organization. International ethical guidelines for health-related research involving humans, 4th edition. Published 2016. Accessed March 30, 2021. https:\/\/cioms.ch\/wp-content\/uploads\/2017\/01\/WEB-CIOMS-EthicalGuidelines.pdf"},{"key":"zoi210232r17","unstructured":"The World Medical Association (WMA). WMA Declaration of Helsinki: ethical principles from medical research involving human subjects. Published October 2013. Accessed March 29, 2021. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/"},{"key":"zoi210232r21","unstructured":"US Food and Drug Administration. Evaluating inclusion and exclusion criteria in clinical trials. Published April 16, 2018. Accessed March 29, 2021. https:\/\/www.fda.gov\/media\/134754\/download"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2779457\/miller_2021_oi_210232_1619553966.17458.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T03:29:11Z","timestamp":1724988551000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2779457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.7075","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]}}}